Mirvetuximab + Rucaparib for Ovarian Cancer

Palo Alto (17 mi)

Overseen byFloor Backes, MD

Age: 18+

Sex: Female

Travel: May be covered

Time Reimbursement: Varies

Trial Phase: Phase 1

Waitlist Available

Sponsor: Ohio State University Comprehensive Cancer Center

No Placebo Group

Breakthrough Therapy

Trial Summary

What is the purpose of this trial?This phase I trial studies the side effects and best dose of mirvetuximab soravtansine and rucaparib camsylate in treating participants with endometrial, ovarian, fallopian tube or primary peritoneal cancer that has come back. Drugs such as mirvetuximab soravtansine are antibodies linked to a toxic substance and may help find certain tumor cells and kill them without harming normal cells. Rucaparib camsylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving mirvetuximab soravtansine and rucaparib camsylate may work better in treating participants with recurrent endometrial, ovarian, fallopian tube or primary peritoneal cancer.

Eligibility Criteria

This trial is for people with certain types of recurrent cancers: endometrial, ovarian, fallopian tube or primary peritoneal cancer. Participants must have tumors that are positive for folate receptor-alpha and should not have low-grade serous or clear cell carcinoma unless they carry a BRCA mutation. They need to be in good physical condition (ECOG ? 1), have adequate organ function, and women must agree to use contraception.

Treatment Details

The trial is testing the combination of mirvetuximab soravtansine (an antibody-drug conjugate) and rucaparib camsylate (a PARP inhibitor) on participants with recurrent cancers mentioned above. It aims to determine the safest doses and observe how well these drugs work together against these cancers.

1Treatment groups

Experimental Treatment

Group I: Treatment (mirvetuximab soravtansine, rucaparib)Experimental Treatment4 Interventions

Participants receive mirvetuximab soravtansine IV on day 1 and rucaparib PO BID on days 1 through 21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

Mirvetuximab Soravtansine is already approved in United States for the following indications:

🇺🇸 Approved in United States as Elahere for: